Table 3. Safety of ALPPS.
| Study | Patients number | 90-day mortality (ratio %) | Complication rate after stage 1 (higher than grade IIIB) (ratio%) | Complication rate after stage 2 (higher than grade IIIB) (ratio%) | Main topic | Main bias based on study design |
|---|---|---|---|---|---|---|
| Albert Chan | 46 | 6.5 | 0 | 8.7 | ALPPS versus PVE for hepatitis-related HCC | Single experience |
| Zhang Wang | 45 | 11.1 | 8.8 | 14.6 | Safety of ALPPS for HCC | Single experience |
| Daryl Chia | 9 | 11.1 | 14.2 | NA | ALPPS for HCC is associated with decreased liver remnant growth | Single experience |
| Qiang Wang | 10 | 40 | 10 | 37.5 | Safety and efficacy of RALPPS | Single experience |
| Xiujun Cai | 12 | 50 | 25 | 4 5 | The ALPPS in the treatment of hepatitis B-related HCC with cirrhosis | Single experience |
| Chang Gung | 5 | 0 | 0 | 0 | Safety of ALPPS for HCC | Single experience |
| Vennarecci | 13 | 12.5 | 0 | 20 | ALPPS for primary and secondary liver tumors | Single experience |
| D’Haese | 35 | 31.4 | NA | NA | Safety of ALPPS for intermediate-stage HCC | Retrospective multicenter |
| Björnsso | 6 | 0 | 0 | 0 | ALPPS in patients with HCC | Single experience |
ALPPS, associating liver partition and portal vein ligation for staged hepatectomy; HCC, hepatocellular carcinoma; PVE, portal vein embolization; NA, not available; RALPPS, radiofrequency-assisted ALPPS.